Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet

Document -

Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet

go to media item
License:
All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
File format:
.pdf

Contacts

Related content

  • Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet


    SELECT-MONOTHERAPY evaluates the safety and efficacy of upadacitinib monotherapy in adult patients with moderately to severely active rheumatoid arthritis and inadequate response to a stable dose of methotrexate1 Upadacitinib (15 mg and 30 mg), once daily, achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity (defined as DAS28[CRP]≤